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Abstract:  
Introduction: The UK government introduced the two-week rule (TWR) to improve the diagnosis and 
treatment of gastrointestinal (GI) cancers. This updated review systematically identifies new articles 
since 2009 and presents an overview of the previous and new findings combined for both upper GI 
cancer (UGCs) and colorectal cancers (CRCs). 
Methods: We analysed all peer-reviewed articles and conference abstracts with GI cancer detection 
rates following TWR referral and/or the proportion of TWR-referred GI cancers from the total number 
diagnosed during the study period. We reported average cancer detection rates and split the data 
according to four time periods to determine whether TWR effectiveness improved over time. 
Results: The average cancer detection rate by the TWR for all studies was 11.6% for CRC and 8.3% 
for UGC. We found a decrease in cancer detection rates over time for CRC from 14.4% in 2000-2002 
to 7.2% in 2009-2012. However, UGC detection rates increased over time from 8.5% in 2000-2002 to 
11.4% in 2005-2008. We found that on average, 30.8% of CRCs and 28.8% of UGCs were detected 
following referrals using the TWR system and that these proportions had increased over time from 
30.6% to 38.4% for CRC and from 26.8% to 52% for UGC. 
Conclusion: The TWR is not still sufficiently effective in diagnosing GI cancers in patients, suggesting 
that the referral guidelines need to be improved. Our findings do suggest that the TWR is being used 
more frequently than alternative routes. 
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BACKGROUND 
The Two-Week Rule (TWR) referral (1) was implementation by the UK’s New Labour government in 
2000 to reduce the number of cancer-related deaths by 20% in people under the age of 75 years by 
2010, thereby saving approximately 130,000 lives (2). The TWR was designed to decrease the time 
taken from General Practitioner (GP) appointment to the diagnosis of a potential cancer to a 
maximum of two weeks. In the case of gastrointestinal (GI) cancers, guidelines (3, 4) were issued to 
advise GPs on the key symptoms required to make a patient eligible for the TWR so as not to 
overload the system with unnecessary referrals but to ensure an increase in early cancer detection 
rates. The TWR referral from the GP would result in the fast tracking of a patient for an upper or 
lower GI endoscopy to diagnose any cancers in the GI tract as quickly as possible, significantly 
improving the health outcome of patients with a subsequently confirmed cancer. 
We have previously reviewed the literature up to 2009 (5, 6), although these reviews did not cover a 
sufficiently long period to determine the true impact of the TWR. The aim of this review was to 
update the data available to determine whether the TWR has improved cancer detection rates in the 
last decade for upper GI cancers (UGCs) and colorectal cancers (CRCs). 
 
METHODS 
A literature search was performed using Pubmed and the Cochrane Library employing a text search 
for peer-reviewed research articles. The search terms used were “colorectal”, “CRC”, “upper 
gastroint*”, “upper GI”, “gastrointestinal”, “oesophageal” and “gastric” in combination with “urgent 
referral*”, “two week*”, “2-week*”, “fourteen day*” and “fast track”. In addition to this, peer-
reviewed abstracts presented at the British Society of Gastroenterology conferences and Association 
of Coloproctology of Great Britain and Ireland Annual Meetings since 2000 were hand-searched to 
locate suitable abstracts for inclusion. Finally, a secondary literature search of all bibliographies was 
done. 
Only peer-reviewed studies commenting on the effectiveness of the TWR in diagnosing GI cancers 
were selected. Studies performed in non-NHS organisations were excluded. Data describing the TWR 
GI cancer detection rate and the proportion of GI cancer patients diagnosed using the TWR identified 
were extracted and split according to cancer type (UGC or CRC).  
Data were extracted into the following four outcomes for analysis: Number of TWR referrals received; 
number of cancers diagnosed from those TWR referrals; TWR cancer detection rate; and the 
proportion of all cancers diagnosed that were referred by the TWR.  
Data were also allocated into one of four sets of three-year time periods according to the study start 
and end dates to determine whether cancer detection rates had improved over time: Jan 2000 and 
Dec 2002 (Group 1); Jan 2003 and Dec 2005 (Group 2); Jan 2006 to Dec 2008 (Group 3) and Jan 
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2009 to Dec 2012 (Group 4). Those studies with no start and end dates reported were allocated into 
a time period which was a minimum of 12 months prior to their publication date. 
 
RESULTS 
After critically appraising all articles and abstracts found in the literature search, there were 57 
research articles and peer-reviewed abstracts with comparable data on CRCs (see Table 1) and 26 
with comparable data on UGCs (see Table 2). 
 
Colorectal Cancers 
When combining the data from all articles we found that of the 28,858 patients with a suspected CRC 
referred by their GP using the TWR, only 2,940 (10.2%) were subsequently diagnosed with CRC. The 
lowest rate was 4.4% (7) and the highest rate was 43% (8). The average cancer detection rate for 
49 studies reporting these data was 11.6%.  
When we split the data according to when the studies were conducted, we found that the average 
cancer detection rate for each time frame was: 14.4% for 25 Group 1 studies; 9.4% for 12 Group 2 
studies; 9.1% for 6 Group 3 studies; and 7.2% for the 6 Group 4 studies. 
We found that on average, 30.8% of CRCs were detected following referral using the TWR as 
opposed to alternative methods such as routine referrals and emergency referrals. When we split the 
data according to when the studies were conducted, we found that the average proportion of CRCs 
detected using the TWR for each time frame was: 30.6% for 19 Group 1 studies; 29.1% for 14 Group 
2 studies; 43% for the single Group 3 study; and 38.4% for the 2 Group 4 studies. 
 
Upper GI Cancers 
When combining the data from all articles we found that of the 10,001 patients with a suspected UGC 
referred by their GP using the TWR, only 692 (6.9%) were subsequently diagnosed with UGC. The 
lowest rate was 2.1% (9) and the highest rate was 24.8% (10). The average cancer detection rate 
for the 26 studies reporting these data was 8.3%. 
When we split the data according to when the studies were conducted, we found that the average 
cancer detection rate for each time frame was: 8.5% for 17 Group 1 studies; 6.2% for 6 Group 2 
studies; and 11.4% for 3 Group 3 studies. No Group 4 studies were retrieved. 
We found that on average, 28.8% of UGCs detected following referral using the TWR as opposed to 
alternative methods such as routine referrals and emergency referrals. When we split the data 
according to when the studies were conducted, we found that the average proportion of UGCs 
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detected using the TWR for each time frame was: 26.8% for 10 Group 1 studies; 24.4% for 6 Group 
2 studies; and 52% for 2 Group 3 studies. No Group 4 studies were retrieved. 
 
DISCUSSION 
For each type of GI cancer, the average cancer detection rate by the TWR was still extremely low 
(11.6%  for CRC and 8.3% for UGC). We found a decrease in cancer detection rates over time for 
CRC from 14.4% in studies starting between 2000-2002 to 7.2% in studies starting between 2009-
2012. However, UGC detection rates increased over time from 8.5% in studies starting between 
2000-2002 to 11.4% for studies starting between 2005-2008. We found that on average, 30.8% of 
CRCs and 28.8% of UGCs were detected following referrals using the TWR system and that these 
proportions had increased over time for both cancer types. 
This paper reviewed all relevant peer-reviewed evidence from studies reporting on the impact of the 
TWR on NHS services. All datasets have been included from all eligible studies for analysis, making 
this review as comprehensive as possible. However, there were a limited amount of peer reviewed 
research articles in this field, so we opted to include peer-reviewed abstracts presented at major 
conferences since 2000. In doing so we identified a total of 84 peer-reviewed publications meeting 
our inclusion criteria and containing comparable, eligible datasets, some for multiple time periods or 
for both GI cancers. 
There were far fewer sources of information on TWR effectiveness for latter study periods compared 
with the years following implementation of the TWR in 2000. For this reason, data for Groups 3 and 4 
were limited and any averages were likely to be representative of a small sample size.  
The low cancer detection rates for CRCs and UGCs following a TWR referral at all intervals suggests 
that the guidelines were not effective at implementation and are still not effective in recent years, 
although the low sample size in latter time periods offer a less reliable picture of TWR effectiveness. A 
recent study called for an evidence-based approach to the referral criteria for suspected CRC (11) as 
existing guidelines are not sensitive or specific enough to identify suspected GI cancers without 
flooding the TWR pathway. For example, there is evidence that the age threshold should be lowered 
(12). It is also possible that GPs are still inappropriately referring patients using the TWR, although 
most hospitals have implemented a triaging system as part of the TWR pathway to screen patients 
prior to an endoscopy. Referral proformas have also been proven to improve guideline compliance, 
resulting in higher cancer detection rates (13). 
This review reports an increase in the proportion of cancers being detected following a TWR referral 
as opposed to other routes such as emergency and routine referrals indicating that of those referred, 
more are being done so correctly via the TWR. It is possible that patients are presenting to their GP 
with the key symptoms requiring a TWR referral rather than having later stage symptoms which end 
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up being emergency referrals. This could be attributed to more prominent health campaigns and 
increased patient awareness of GI cancer. 
The TWR has placed a significant burden on the resources of most gastroenterology services in the 
NHS with little gain in identifying malignancies (14). Most hospitals have a dedicated TWR referral list 
to ensure their Trust meets the strict two-week target. This should, in theory, have a negative impact 
on all other aspects of the service, although little evidence of this has been found to date. Three 
studies reported a decline in the routine endoscopy waiting lists following the introduction of the TWR 
(7, 15, 16), possibly due to an increased awareness of the guidelines for patient referrals, the more 
efficient organisation of services or the introduction of nurse endoscopists to cope with increased 
demand.  
What little evidence exists on the short and long term effect of the TWR suggests no significant 
benefits in survival for CRC (17-21). This is most likely because those identified via the TWR present 
to their GP with classic symptoms of GI cancers which, whilst making them eligible for fast tracking 
and a reduced time to diagnosis and treatment, also mean that they are likely to be in the later, less 
treatable stages of the disease.  
To summarise, we have strong evidence of consistently low GI cancer detection rates and even 
though more cancer patients are being referred via the TWR, many studies are reporting no 
difference in survival compared with those diagnosed using alternative routes. The findings suggest 
that there is a need to consider revising or replacing the TWR as in its current state, as there appears 
to be limited health benefits to be gained by patients  
 
CONCLUSION 
The findings of this review suggest that after more than 10 years, the TWR still has low cancer 
detection rates for both CRCs and UGCs. An update to the guidelines for GPs may be necessary to 
better screen patients and increase cancer detection rates, whilst patients should be continuously 
encouraged to visit their GP with any worrying symptoms so that cancers can be detected and treated 
earlier.  
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Table 1. Studies retrieved with TWR data for CRC, ordered alphabetically. 
 
Author (ref) Time period No. TWR referrals 
No. CRCs 
detected 
CRC 
detection 
rate (%) 
% CRCs 
diagnosed 
via TWR 
Start 
period 
assigned 
Adeosun (22) Not stated 319 29 9.1 20.5 1 
Aljarabah (23) Apr-Sept 06 217 22 10.1 - 3 
Allgar (24) Jan-01 to Dec-02 632 51 8.1 21.3 1 
Anderson (25) Jan-02 to Dec-05 978 78 8.0 - 2 
Aryal (26) Not stated - - - 35 1 
Ballal (27) Not stated 508 57 11 - 1 
Barrett (8) Jan-Dec 02 - - 43 27.9 1 
Barwick (28) Jan-Aug 01 144 14 9.7 - 1 
Baughan (29) Jan-Jul 2008 3370 452 13.4 - 3 
Bennis (30) Aug-02 to Jul-03 388 164 42.3 - 1 
Bevis (31) Oct-02 to Sept-04 - 97 - 50.2 2 
Bhangu (32) Jan-06 to Jul-09 1725 108 6.3 - 3 
Boulton-Jones (33) Not stated 394 46 11.7 37.4 1 
Chandran (34) Jan to Dec 01 275 48 17.4 29.9 1 
Jan to Dec 02 - - - 29.9 1 
Jan to Dec 03 - - - 33.9 2 
Jan to Dec 04 470 62 13.1 32.6 2 
Chaudhri (35) Not stated 243 115 6.2 - 1 
Chohan (36) Jul-00 to Dec-01 462 64 13.9 32.8 1 
Currie (21) Jan-00 to Dec-05 - - - 41 1 
Davies (37) Nov-99 to Oct-02 2294 257 11.2 40.5 1 
Debnath (38) Aug-00 to Jul-01 237 21 8.9 21.9 1 
Eccersley (39) Jun-00 to May-01 173 26 15 17.9 1 
El-Himadie (40) Jan-Dec 05 482 49 10.2 - 2 
Jan-Dec 10 915 66 7.2 - 4 
Flashman (41) Jul-00 to Jun-01 758 65 8.6 26.1 1 
Foster (42) Oct-00 to Sept-01 147 10 6.8 9.5 1 
Foster (43) Not stated - - - 8 1 
Gandy (44) Jun-00 to Nov-01 543 73 13.4 - 1 
Glancy (45) Aug-00 to Nov 01 326 32 9.8 - 1 
John (46) Apr-04 to Mar-05 534 60 11.2 34.3 2 
John (47) Not stated - - - 43 3 
Leung (48) Not stated 1100 81 7.3 37 4 
Linn (49) Jan-Jun 06 381 27 7.1 - 3 
MacDonald (50) Not stated 50 6 12 - 1 
Maruthachalam (51) Jan-Dec 03 188 19 10.1 - 2 
Marsden (52) May-03 to Oct-04 - - - 12 2 
Maruthachalam (53) Mar-04 to Jun-05 96 9 9.4 - 2 
Moreea (54) Not stated 25 4 16 - 1 
Padwick (11) Jan-Dec 10 940 50 5.3 39.7 4 
Peacock (55) Feb-Apr 2012 544 32 6 - 4 
Rai (56) Not stated 1000 100 10 25 2 
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Not stated 222 14 6 15.9 2 
Rao (7)  Jun-Dec 03 319 14 4.4 25.9 2 
Schneider (20) Oct-02 to Sept-04 - - - 51 2 
Scott (57) Not stated - - - 10.6 2 
Shabbir* (12) Jan-01 to Dec-05 - 9 - 24 2 
Shaw (58) Sept-05 to Sept-06 204 12 5.9 - 3 
Shenderey (59) Jan-Dec 03 - - - 28.9 2 
Sidhu (60) Jan-Jun 03 122 13 10.7 26.5 2 
Smith (61) Jan-02 to Dec-04 2748 174 6.3 36.4 2 
Spencer (62) Jul-Dec 2000 243 36 14.8 - 1 
Stoker (63) Not stated 151 18 11.9 - 1 
Stone (10) Jan-Sept 00 264 37 14 - 1 
Taylor (64) Jan-Dec 01 - - 17.4 - 1 
Jan-Aug 04 - - 12.9 - 2 
Trickett (65) Nov-00 to Oct-01 - 30 - 20.4 1 
Vaughan-Shaw (66) * Jul-07 to Jul-11 2735 214 7.8 - 4 
Vaughan-Shaw (67) Dec-11 to Jun-12 397 37 9.3 - 4 
Vieten (68) Mar-00 to Dec-01 420 51 12.1 37 1 
Vijayan (69) Not stated 102 12 12 - 3 
Walsh (16) Aug-Oct 00 73 11 15.1 47.8 1 
Zafar (17) Jan-Dec 02 - - - 77 1 
 
NOTES:  
Start period was coded (1=2000-2; 2=2003-5; 3=2006-8; 4=2009-12). Where no date was available, the authors checked the 
submission date for the article and selected the code which was ~12 months prior to that date. 
* Patients aged <50y only 
**Includes repeat referrals 
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Table 2. Studies retrieved with UGC detection rates via TWR, ordered alphabetically. 
 
Author (ref) Time period No. TWR referrals 
No. UGCs 
detected 
UGC 
detection 
rate (%) 
% UGCs 
diagnosed 
via TWR 
Start 
period 
assigned 
Aung (70) Sept-00 to Dec-01 307 29 9.4 27.6 1 
Barbour (71) Oct-01 to Mar-02 172 17 9.9 48.6 1 
Baughan (29) Jan-Jul 08 1844 207 11.2 - 3 
Boulton-Jones (33) Not stated 280 27 9.6 35.5 1 
Cairns (72) Jan-02 to Mar-04 - - - 55 1 
Carty (9) Jan-01 to Dec-01 191 4 2.1 25 1 
Dewar (73) Jan-04 to Dec-04 321 12 3.7 16 2 
Gera (74) Jan-02 to Dec-02 157 6 3.8 10.5 2 
Jan-04 to Aug-04 175 16 9.1 51.6 2 
Jan-05 to Dec-05 261 24 9.2 38.7 2 
Irving (75) Apr-0- to Apr-08 295 34 11.5 64.2 3 
Kapoor (76) Jul-00 to Feb-02 1852 70 3.8 - 1 
Mar-02 to Feb-03 1785 52 2.9 - 1 
Lassman (77) Not stated 79 12 15.2 - 1 
Loehry (78) Apr-01 to Sept-01 79 3 3.8 - 1 
Mahmood (79) Not stated 45 2 4.4 - 1 
Mohammed (80) Nov-99 to Dec-01 - 16 - 11.1 1 
Moran (81) Jan-03 to Dec-03 356 18 5.1 14.5 2 
Ng (82) Oct-03 to Mar-04 125 8 6.4 15.1 2 
Patel (83) Apr-06 to Oct-07 345 36 11.4  3 
Radbourne (84) Jul-00 to Dec-01 153 16 10.5 14.7 1 
Reilly (85) Aug-00 to Jul-01 79 8 10.1 26.7 1 
Sharpe (19) Jan-06 to Dec-07 - 135 - 39.7 3 
Spahos (15) Sept-00 to Aug-02 623 38 6.1 15.4 1 
Spencer (62) Jul-Dec 00 222 28 12.6 - 1 
Stoker (63) Not stated 112 7 6.3 - 1 
Stone (10) Jan-Sept 00 105 26 24.8 - 1 
Subramanian (86) Jul-00 to Aug-01 199 11 5.5 - 1 
Warner (87) Not stated 146 10 6.8 8.7 1 
 
NOTES:  
Start period was coded (1=2000-2; 2=2003-5; 3=2006-8; 4=2009-12). Where no date was available, the authors checked the 
submission date for the article and selected the code which was ~12 months prior to that date. 
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